RE: REACH RNS out8 Jan 2025 09:16
Got it
Dr Peter Sargent, CEO, commented: "Physiomics and our partners are thrilled to have now obtained approval to proceed with the PREDICT-ONC observational trial. We had initially planned to start this trial last summer, but due to delays in the approval process that were out of our hands, approval has only now been obtained. However, due to the hard work of the project team, including recruitment of a research nurse and proactive identification of potential patients, we predict that these delays will have minimal impact on the overall timelines and final readout of the project. We at Physiomics are excited to start receiving the data generated from this trial, so we can continue development of our Personalised Dosing Software".